Le Lézard
Classified in: Health
Subjects: PDT, FDA

Mundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer


- T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2

- Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant unmet patient need

BASEL, Switzerland, March 28, 2019 /PRNewswire/ -- Mundipharma EDO GmbH, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to tinostamustine, an alkylating deacetylase inhibiting molecule for the treatment of T-cell prolymphocytic leukaemia (T-PLL).3

The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. T-PLL is an extremely rare and typically aggressive blood cancer.  It is so rare that healthcare professionals may only see one case of T-PLL every five to 10 years.4 Due to its rarity, T-PLL can be misdiagnosed, resulting in poor patient outcomes.4 Patients have a median survival of around seven months to one year, and the disease is typically resistant to conventional chemotherapy.4,5

Dr Thomas Mehrling, CEO of Mundipharma EDO added: "Currently there are no licensed treatment options for T-PLL, therefore, the development of new therapeutic approaches is essential for these patients.  We are pleased that the FDA has granted tinostamustine orphan drug designation in this area. At Mundipharma EDO, our focus is to develop treatments for rare and difficult-to-treat cancers, such as T-PLL, and we are progressing the development of tinostamustine in early phase clinical trials, in conjunction with Imbrium Therapeutics."

To find out more about tinostamustine and the Mundipharma EDO oncology clinical trials programme and view the full press release visit: www.edoncology.com  


  1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition) IARC: Lyon 2017 (pg 272)
  2. T-cell prolymphocytic leukemia (T-PLL) information page. Leukemia and Lymphoma Society. Available at: https://www.lls.org/leukemia/t-cell-prolymphocytic-leukemia-t-pll. Last accessed 26 March 2019.
  3. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=636418. Last accessed 26 March 2019.
  4. Dearden C. Blood. 2012; 120(3):538?55.
  5. NIH NCI SEER Database. Available at: https://seer.cancer.gov/seertools/hemelymph/51f6cf58e3e27c3994bd53f3/. Last accessed 26 March 2019.


These press releases may also interest you

17 jan 2020
Loden Vision Centers, a leading comprehensive ophthalmology company with 5 locations across the greater Nashville and surrounding areas, today announced the appointment of the senior executive, Matthew Pierre, to serve as its Chief Executive Officer....

17 jan 2020
The New Year is traditionally a time for resolutions.  Celebrity lifestyle expert Valerie Greenberg has tips for creating a "new you" for the new year. POPULAR RESOLUTION Have a fitness plan that is easy. One solution is in-home fitness...

17 jan 2020
Alan Alda, the Emmy Award-winning actor, director and writer who has become a leading advocate for effective science communication, has partnered with the renowned scientific institute Scripps Research to bring immersive communication training to...

17 jan 2020
The global PD-1 and PD-L1 inhibitors market is poised to grow by USD 21.2 billion during 2019-2023, progressing at a CAGR of over 19% during the forecast period. Request Free Sample Pages Read the 118-page research report with TOC on "PD-1 and...

17 jan 2020
Therapy and Beyond, a leading provider of autism treatment for individuals, will expand its applied behavior analysis and autism therapy programs to a new location in Sugar Land, TX. About Applied Behavior Analysis Applied Behavior Analysis (ABA...

17 jan 2020
Summary Product: PMS-Nystatin Oral Suspension 100,000 units/mL (DIN 00792667), Lot 681044, Expires 30-11-2021. Issue: Product may contain clumps or jelly-like material, which may lead to choking. Newborns, infants and people with difficulty...

News published on 28 march 2019 at 09:30 and distributed by: